<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Syndax Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc</link>
<description>Latest news and press releases for Syndax Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/syndax-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c1f678dffbe2df119210.webp</url>
<title>Syndax Pharmaceuticals Inc</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc</link>
</image>
<item>
<title>Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-to-announce-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-to-announce-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-april-30-2026</guid>
<pubDate>Fri, 24 Apr 2026 11:00:00 GMT</pubDate>
<description>NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, April 30, 2026. The live audio webcast and accompanying</description>
</item>
<item>
<title>Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25,</description>
</item>
<item>
<title>Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-and-webcast-on-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-and-webcast-on-february-26-2026</guid>
<pubDate>Thu, 19 Feb 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, February 26, 2026. The live audio webc</description>
</item>
<item>
<title>Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-participation-2026-guggenheim-emerging-outlook-biotech-summit-2026</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-participation-2026-guggenheim-emerging-outlook-biotech-summit-2026</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer</description>
</item>
<item>
<title>Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-pharmaceuticals-reports-inducement-grants-210100886</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-pharmaceuticals-reports-inducement-grants-210100886</guid>
<pubDate>Wed, 04 Feb 2026 21:01:00 GMT</pubDate>
<description>NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February 1, 2026, the Company granted inducement awards to purchase up to 11,600 shares of common stock to two new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement</description>
</item>
<item>
<title>Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-reports-preliminary-2025-financial-highlights-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-reports-preliminary-2025-financial-highlights-and-provides-business-updates</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued</description>
</item>
<item>
<title>Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-and-world-orphan-drug-alliance-launch-multi-regional-managed-access-program</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-and-world-orphan-drug-alliance-launch-multi-regional-managed-access-program</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched</description>
</item>
<item>
<title>Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-presentation-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-presentation-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer</description>
</item>
<item>
<title>Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/revuforjr-revumenib-named-best-new-drug-scrip-awards-2025-2025-12-12</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/revuforjr-revumenib-named-best-new-drug-scrip-awards-2025-2025-12-12</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer</description>
</item>
<item>
<title>Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-highlights-leadership-menin-inhibition-ash-2025-multiple-revuforjr-revumenib</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-highlights-leadership-menin-inhibition-ash-2025-multiple-revuforjr-revumenib</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among</description>
</item>
<item>
<title>Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-participation-8th-annual-evercore-healthcare-conference-2025-12-01</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-participation-8th-annual-evercore-healthcare-conference-2025-12-01</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer</description>
</item>
<item>
<title>Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>– $45.9 million in total revenue, representing 21% growth over 2Q25 – – $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25</description>
</item>
<item>
<title>Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-host-ash-investor-event-person-and-webcast-december-8-2025-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-host-ash-investor-event-person-and-webcast-december-8-2025-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer</description>
</item>
<item>
<title>Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-compelling-revuforjr-revumenib-and-niktimvotm-axatilimab-csfr-data</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-compelling-revuforjr-revumenib-and-niktimvotm-axatilimab-csfr-data</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R</description>
</item>
<item>
<title>Syndax Announces Participation in November Investor Conferences</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-participation-november-investor-conferences-2025-10-30</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-participation-november-investor-conferences-2025-10-30</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer</description>
</item>
<item>
<title>Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announce-third-quarter-2025-financial-results-and-host-conference-call-and</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announce-third-quarter-2025-financial-results-and-host-conference-call-and</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer</description>
</item>
<item>
<title>Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-fda-approval-revuforjr-revumenib-adult-and-pediatric-patients</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-fda-approval-revuforjr-revumenib-adult-and-pediatric-patients</guid>
<pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
<description>– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – –</description>
</item>
<item>
<title>CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/create-medicines-strengthens-executive-team-with-appointment-of-veteran-biopharma-leader-allan-l-shaw-as-cfo-and-cbo</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/create-medicines-strengthens-executive-team-with-appointment-of-veteran-biopharma-leader-allan-l-shaw-as-cfo-and-cbo</guid>
<pubDate>Wed, 08 Oct 2025 12:00:00 GMT</pubDate>
<description>CREATE Medicines, a clinical-stage biotechnology company pioneering RNA-based in vivo multi-immune programming, today announced the appointment of Allan L. Shaw as Chief Financial Officer (CFO) and Chief Business Officer (CBO). Mr. Shaw, an accomplished industry leader with more than 20 years of experience guiding biopharmaceutical companies through critical phases of growth, will oversee CREATE Medicines' financial strategy, capital formation, and business development initiatives as the company</description>
</item>
<item>
<title>Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndaxs-revuforjr-revumenib-included-nccn-clinical-practice-guidelines-oncology-nccn</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndaxs-revuforjr-revumenib-included-nccn-clinical-practice-guidelines-oncology-nccn</guid>
<pubDate>Fri, 19 Sep 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer</description>
</item>
<item>
<title>Syndax Announces Participation in September Investor Conferences</title>
<link>https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-participation-september-investor-conferences-2025-08-26</link>
<guid isPermaLink="true">https://6ix.com/company/syndax-pharmaceuticals-inc/news/syndax-announces-participation-september-investor-conferences-2025-08-26</guid>
<pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
<description>NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer</description>
</item>
</channel>
</rss>